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Cytological surveillance compared with immediate referral
for colposcopy in management of women with low grade
cervical abnormalities: multicentre randomised controlled
trial
TOMBOLA Group
ABSTRACT
Objectives To examine the effectiveness of cytological
surveillance in primary care compared with immediate
referral for colposcopic examination in women with low
grade abnormal results on cervical cytology tests.
Design Multicentre individually randomised controlled
trial.
Setting NHS cervicalscreeningprogrammes in Grampian,
Tayside, and Nottingham.
Participants 4439 women, aged 20-59, with a cytology
result showing borderline nuclear abnormalities or mild
dyskaryosis, October 1999-October 2002.
Interventions Cytological screening every six months in
primary care (n=2223) or referral for colposcopy and
related interventions (n=2216). All women were followed
for three years, concluding with an exit appointment at
which colposcopic examination was undertaken.
Colposcopists assessing outcome at this appointment
were blinded to randomisation.
Main outcome measures Primary end point: cumulative
incidence of cervical intraepithelial neoplasia grade II or
more severe disease. Other end points: cervical
intraepithelial neoplasia grade III or worse, clinically
significant anxiety and depression, other self reported
after effects, and rates of non-attendance. Analysis was
byintentionto treat;allthose randomisedwereincluded.
Results The cumulative incidence of cervical
intraepithelial neoplasia grade II or worse was 79 per
1000 person years in the colposcopy arm and 58 per
1000 person years in the cytological surveillance arm
(relative risk 1.37, 95% confidence interval 1.19 to 1.57).
Thisdifferencewaslessmarkedforcervicalintraepithelial
neoplasia grade III or more severe disease, but the
incidence was still higher in the colposcopy arm (relative
risk 1.26, 1.04 to 1.53). Among women randomised to
immediate colposcopy, 79% (74.9% to 82.5%) of cases
ofcervicalintraepithelialneoplasiagradeIIorworsewere
diagnosedatthetimeoftheimmediatecolposcopy,while
among women randomised to cytological surveillance,
77% (72.1% to 81.2%) of cases were detected by
surveillance cytology and related interventions. Similar
proportions of women were anxious or depressed in the
twoarms.Ahigherproportionofwomeninthecolposcopy
arm reported after effects, and these were of longer
duration and more severe. Non-attendance was low in
both arms.
Conclusion The more marked difference between the
arms in the occurrence of cervical intraepithelial
neoplasiagradeIIorworsethanintheoccurrenceofgrade
III or worse can probably be accounted for by the
spontaneous regression of some cases of grade II
neoplasia. Compared with cytological surveillance, a
policy of immediate colposcopy detects more cervical
intraepithelial neoplasia grade II or worse, and some
more grade III or worse, but might lead to overtreatment.
Such a policy is associated with a higher rate of reported
aftereffects,whicharemoresevereandoflongerduration
than those associated with cytological surveillance.
Trial registration ISRCTN 34841617.
INTRODUCTION
Organised cervical cytological screening programmes
have reduced mortality from cervical cancer,
1-5 but
they cannot eliminate risk. The challenge in the future
development of these programmes is to reach an opti-
mum balance between benefit, harm, and
affordability.
6 The initial cytological screening test
detects changes in cervical cells that are common. For
example, in the UK National Health Service (NHS)
cervicalscreeningprogrammesoveraquarterofamil-
lion cytology tests showing low grade abnormalities
are reported each year.
7 The number of women with
screen detected abnormal cytology is about 20-fold
higher than the number expected to develop cervical
cancer in the absence of screening, and about 60-fold
higher than the number who would die from cervical
cancer.
8 Two methods of managing women with low
grade abnormalities—that is, borderline nuclear
abnormalities or mild dyskaryosis—are routinely
used: cytological surveillance (repeat cytology tests in
primary care) or immediate referral for colposcopic
examination in a hospital outpatient clinic.
9 There
has been prolonged controversy as to which method
is the more effective and efficient.
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concern that some cases of high grade disease might
escape detection because of non-attendance or limited
sensitivity and that women might experience anxiety
overaprolongedperiod.
7Moreover,anestimated65%
of women with mild dyskaryosis will eventually be
referred for colposcopy.
12 By contrast, a policy of
immediate referral for colposcopy has raised concerns
about possible overtreatment,
1314 complications,
15
effect on subsequent pregnancy,
16 high levels of
anxiety,
1718resourceconstraintsingeneral,
19andwait-
ing times.
1920 Consequently, there is considerable var-
iation in practice between countries.
21 The guidelines
for the English NHS cervical screening programme
reflect the uncertainty—“women should be referred
for colposcopy after one test reported as mild dyskar-
yosis,butitisacceptabletorecommendarepeattest”
22
—whereas Scottish guidelines continue to defer refer-
ral for colposcopy until after two mildly dyskaryotic
results.
23 In both jurisdictions, colposcopic referral
for women with borderline nuclear abnormalities is
recommended only after three such results are
reported,butinrecentyearstherehasbeenanincreas-
ing tendency to refer sooner.
24
There have been few direct comparisons of these
alternative managements. The ALTS trial in the Uni-
ted States concluded that women whose index cytol-
ogy showed low grade squamous intraepithelial
lesions (broadly comparable with mild dyskaryosis)
would best be managed by immediate colposcopy.
25
For women whose index cytology showed atypical
squamouscellsofuncertainsignificance(broadlycom-
parablewithborderlinenuclearabnormalities),cytolo-
gicalsurveillanceresultedinasimilarlevelofdetection
of cervical intraepithelial neoplasia grade III or more
severe disease as immediate colposcopy, while redu-
cing the proportion of women referred for
colposcopy.
26 In two studies in the UK that included
women with low grade abnormal cytology, women
were randomised to immediate colposcopy or to sur-
veillance, with different periods of follow-up.
2728 In
one of these, the frequency of cervical intraepithelial
neoplasia grade II or worse was somewhat higher in
the group offered immediate colposcopy than in the
three groups offered surveillance over different
periods,
27 and the other observed no difference
between the proportions with cervical intraepithelial
neoplasia grade II or worse at immediate colposcopy
or after 24 months of cytological follow-up.
28 In one
otherfollow-upstudyofwomenwithmilddyskaryosis
in the UK, the proportion with cervical intraepithelial
neoplasia II or worse was lower in women undergoing
cytological surveillance than in those who underwent
immediate colposcopy,
29 but no adjustment was made
for differences between the groups in sociodemo-
graphiccharacteristicsandriskfactorsforcervicalneo-
plasia.
The psychological effects of alternative manage-
ments, and women’s preferences, are largely
unknown.
7 In a UK trial assessing the psychological
effects of cytological surveillance compared with
those of having a choice between this form of manage-
mentandimmediatecolposcopyinwomenwithrecur-
rent borderline nuclear abnormalities or mild
dyskaryosis, there was no difference in psychological
morbidity over a 12 month period.
30 Studies of
hypothetical scenarios in the US suggest that women
prefer colposcopy when the index cytology is more
severe, but otherwise prefer cytological
surveillance.
3132
There is a need for comprehensive evaluation of the
effectsofalternativemanagements,comparingclinical
effectiveness,psychologicalandotheraftereffects,and
cost effectiveness. The Trial Of Management of Bor-
derline and Other Low grade Abnormal smears
(TOMBOLA), a pragmatic randomised controlled
trial set within the cervical screening programmes in
Scotland and England, compared the effectiveness
and efficiency of cytological surveillance in primary
care and immediate colposcopy for women with low
grade cervical abnormalities and considered whether
testing for human papillomavirus infection of types
associated with a high risk for cervical cancer
33 might
helpappropriatemanagementdecisions.
24Wepresent
dataonthedetectionofcervicalintraepithelialneopla-
siagradeIIorworse,anxietyanddepression,andother
after effects. Other aspects of the study are presented
elsewhere.
34
METHODS
Design, participants, and procedures
Full details of the design, eligibility criteria, recruit-
ment methods, human papillomavirus testing, inter-
ventions, follow-up, and outcome assessment have
been described previously.
24 Briefly, the trial invited
women aged 20-59 living in Grampian, Tayside, and
Nottingham,whoseindexcytologyindicatedmilddys-
karyosisorborderlinenuclearabnormalityinOctober
1999-October 2002 to take part. There were two
phases of recruitment. During the first phase (October
1999-March2001),womenwhoseindexcytologyindi-
cated borderline nuclear abnormality were eligible for
inclusion only when a cytology test six months later
indicated borderline nuclear abnormality or mild dys-
karyosis; this was not required in the second phase
(March 2001-October 2002). This change was made
primarily because of increasing pressure in the UK to
refer women with a single result indicating borderline
nuclearabnormalitytocolposcopy,soitwasimportant
that the value of such a change be evaluated before
there was widespread change in practice.
24
Women were invited to attend a recruitment clinic
and, after informed consent, completed sociodemo-
graphic and lifestyle questionnaires. An endocervical
swab was taken for human papillomavirus testing
(further details elsewhere).
24 Randomisation to cytolo-
gicalsurveillanceorimmediatecolposcopywasunder-
taken after the endocervical sample was analysed (one
to four weeks after recruitment), with a dedicated
touch-tone telephone randomisation service provided
by the health services research unit of Aberdeen
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group, index cytology result, result of test for human
papillomavirus infection, and recruitment centre to
ensure balance between the arms.
Cytological surveillance involved repeat cytology
testseverysixmonthsinprimarycare.Afterthreecon-
secutive normal results a woman returned to “routine
recall” (that is, cytology tests at three or five year inter-
vals, according to guidelines at that time). If a woman
had moderate dyskaryosis or worse, or had three con-
secutiveinadequateresults,shewasreferredtoanNHS
colposcopyclinic,accordingtocervical screeningpro-
gramme guidelines.
2223 Otherwise, she remained on
recall for cytology tests every six months for the trial
duration.
The immediate colposcopy arm involved colpo-
scopic examination of the cervix at a hospital outpati-
ent clinic. Women who attended were invited to
participate in a second randomisation, described in
detail in a companion paper.
35 Those who consented
were assigned to either immediate large loop excision
ofthetransformationzone(henceforthlargeloopexci-
sion) or immediate biopsies with selective recall for
large loop excision.
No additional procedures were carried out if the
transformation zone appeared normal at colposcopy.
If colposcopy was inadequate, the woman was treated
according to local NHS protocols. Women with an
adequatecolposcopy and an abnormal transformation
zonereceivedthetreatmentassignedinthesecondran-
domisation. For the women undergoing biopsy, up to
four targeted punch biopsies were taken; the number
of biopsies has been identified as the most important
factor to identify disease.
3637 For a minority of women
in whom the result of the biopsy or large loop excision
histology was worse than cervical intraepithelial neo-
plasia grade III, or in whom there was an indication of
involved margins, postcolposcopy follow-up was
according to local NHS protocols. For most women
follow-up involved cytology tests annually or every
six months either in primary care or colposcopy
clinics, the results of which determined the date for
the next cytology test or re-referral to colposcopy.
Women who declined the second randomisation
underwent a colposcopic examination and any requi-
site procedures (according to local practice) and
returned to primary care for follow-up. Women who
did not attend either of the two colposcopy appoint-
ments offered according to trial protocol were mana-
ged according to local NHS protocols. To avoid bias,
all women were invited to the exit examination (see
below) and included in the intention to treat analysis.
Women were followed up for three years. During
this time, the results of any cytology or colposcopies
undertakenintheNHSwerecapturedonthetrialdata-
base. Three years after recruitment, all women were
invited back to the trial clinic for an exit examination
that included a colposcopy, with large loop excision if
the transformation zone was abnormal. The colposco-
pist was blinded to the woman’s initial cytology status,
her randomisation(s), and any clinical outcomes to
minimise potential bias in assessment of the transfor-
mationzone.Inaddition,aroundthescheduledtimeof
the exit appointment and irrespective of attendance at
this appointment, the woman’s medical records,
together with hospital and pathology databases, were
reviewedto ascertain detailsofanyadditionalrelevant
events and procedures, such as referral with cervical
intraepithelial neoplasia.
Quality assurance
Trial colposcopists were accredited by the British
Society for Colposcopy and Cervical Pathology. The
cytopathology and histopathology laboratories in the
trial centres participate in national quality assurance
schemes. To assess consistency in cytological grading,
slides of different cytological grade were circulated
between trial cytopathologists. One or two indepen-
dent pathologists who were not aware of the original
histopathological results centrally reviewed histology
samples, including those from large loop excision and
punch biopsy, from a random sample of 272 partici-
pants. In 252 cases, the review diagnosis was identical
to the original diagnosis, yielding a κ of 0.9, indicating
good agreement.
Outcomes
Cervical intraepithelial neoplasia grade II or worse—The
primary outcome wasthe cumulative incidence of cer-
vical intraepithelial neoplasia grade II or worse over
the period from recruitment up to and including the
threeyearexitexamination.Ascervicalscreeningpro-
grammesaimtodetectandtreatpremalignantcervical
lesions, cervical intraepithelial neoplasia grade II or
more severe disease is a widely accepted surrogate.
We also considered the point prevalence of cervical
intraepithelial neoplasia grade II or worse detected at
the exit examination. This could have been a result of
failuretodetectcervicalintraepithelialneoplasiagrade
II or worse earlier, failure to treat it adequately, or
newly incident disease that had developed during the
interval since the last examination or treatment. We
also considered cervical intraepithelial neoplasia
grade III or worse as this has been considered in pre-
vious studies.
2526 Similar to ALTS,
2526 we defined
“management success” for a policy of immediate col-
poscopy as the proportion of cervical intraepithelial
neoplasia grade II or worse detected at the time of the
immediate colposcopy (as distinct from during follow-
up or at exit) and management success for a policy of
cytological surveillance as the proportion of cervical
intraepithelial neoplasia grade II or worse detected
during the surveillance period (as distinct from
detected at exit).
Referral for colposcopy during follow-up—In view of a
previous estimate that a high proportion of women
with mild dyskaryosis will eventually be referred for
colposcopy,
12 we examined the proportions of
women referred for colposcopy in the cytological sur-
veillance arm during follow-up (that is, excluding the
exitappointment)andtheproportionintheimmediate
colposcopy arm(excluding the immediate colposcopy
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This was important in relation to anxiety, depression,
and other after effects, as well as in relation to impact
on resources and wait times.
Anxiety,depression,andotheraftereffects—Inthesecond
phase of the trial, information on psychosocial seque-
lae was collected at multiple time points. The hospital
anxiety and depression scale evaluated anxiety or
depression, or both, associated with the alternative
managements.
38 Following established practice, we
categorised women as possibly having depression if
they had a score of 8 or more on the depression scale
andaspossiblyhavinganxietyiftheyhadascoreof11
or more on the anxiety scale.
39 Also in the second
phase, women completed postal questionnaires about
short term after effects of management, specifically
pain, bleeding, and discharge together with the dura-
tion (in number of days) and severity. Severity of pain
was recorded on a five point scale (very mild, mild,
moderate,severe,orverysevere)andseverityofbleed-
ing and discharge also on a five point scale (ranging
from very light to very heavy). The postal question-
naires were scheduled six weeks after the first surveil-
lance cytology test in the cytology arm and six weeks
after the colposcopy or any related procedures or
appointments in the colposcopy arm. Full details of
psychosocial and other after effects are reported
elsewhere.
40
Non-attendance—We counted women as non-atten-
ders if they did not attend for a cytology test or
attended more than six months after it was due. In the
immediate colposcopy arm, non-attenders failed to
attend the two appointments offered.
Statistical analysis
Analyseswereconductedonanintentiontotreatbasis.
We excluded from all analyses women who were ran-
domised and subsequently found to be ineligible for
the trial.
41 To take account of variation between
women in length of follow-up, each woman accrued
person years from the randomisation date until the
date of their exit examination for those who attended
or,forothers,thedatetheexitappointmentwassched-
uled, they requested to leave the trial, had a hysterect-
omy,died,ormovedoutofthearea.Wecomparedthe
cumulative incidence of cervical intraepithelial neo-
plasiagradeIIorworseforimmediatecolposcopyver-
sus cytological surveillance using relative risks and
associated 95% confidence intervals computed by
Poisson regression. Risk estimates were adjusted for
the stratification factors (age group, index cytology,
human papillomavirus result, and recruitmentcentre).
Adjustment for additional sociodemographic and life-
style factors, including deprivation level, reproductive
history, smoking status, use of hormonal contracep-
tion, marital status, ethnic group, and level of physical
activity, had little effect on the risk estimates. We
repeated the analysis stratified by age (20-29, 30-59)
and index cytology (borderline nuclear abnormality,
mild dyskaryosis). In addition, we restricted an analy-
sistowomenwhohadnopreviousabnormalresultson
cytology.Wecomparedtimetodiseasedetectionsince
randomisation between the arms using Kaplan-Meier
curvesandlogranktests(womenwithoutdiseasewere
censored at the end of their follow-up).
We compared the proportions of women with clini-
callysignificantanxietyordepression,orboth,andthe
proportions reporting pain, bleeding, or discharge
between the trial arms, using tests for differences in
proportions. The binomial distribution was used to
compute exact confidence intervals for proportions.
The medians and associated interquartile ranges for
duration of reported pain, bleeding, and discharge
were calculated.
Statistical power
We estimated that a sample size of about 4500 women
would have 80% power to detect a relative risk of 1.15
in cumulativeincidenceofcervical intraepithelial neo-
plasia grade II or worse and 95% power to detect a
relative risk of 1.2 (assuming an overall cumulative
incidence of cervical intraepithelial neoplasia grade II
or worse of 15% and α=0.05 for a two sided test). We
calculated that this sample would have 80% power to
detectadifferenceof6%inthecumulativeproportions
of clinically significant anxiety or depression, or both,
and 90% power to detect a difference of 7% (assuming
an overall cumulative proportion of clinically signifi-
cant anxiety and depression, or both, of 30% and
α=0.05 for a two sided test).
RESULTS
Figure 1 summarises recruitment, randomisation, and
follow-up of this part of the trial. (A flow chart of the
entire trial is on bmj.com.) Of the 11019 women iden-
tifiedaspotentiallyeligibletoparticipate,6504(59.0%)
attended an appointment to have initial eligibility
assessed, of whom 5521 proved to be initially eligible
and consented to randomisation. Of these, 4439 were
confirmedaseligibleandrandomised,2223(50.1%)to
cytological surveillance in primary care and 2216
(49.9%) to immediate colposcopy. Of these, 1296
(58.3%) women in the cytological surveillance arm
and 1389 (62.7%) in the colposcopy arm attended the
exit examination.
The women in the two arms were similar in terms of
the factorsonwhich randomisation wasstratified (cen-
tre, age group, index cytology, and human papilloma-
virus status at recruitment) and in sociodemographic
characteristics(table 1).Aboutathirdhadmilddyskar-
yosis,and43.5%ofthoseprovidingasamplehadinfec-
tion with human papillomavirus of a type associated
with high risk for cervical cancer. Most women were
white,hadbeenbornintheUK,andwereinfullorpart
time employment. About two thirds had ever been
pregnant, and the age at first pregnancy was similar
between trial arms (data not shown). Among current
and former smokers, the distributions by pack years
and years of smoking were similar between the groups
(data not shown).
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grade III or worse
Over the full period of follow-up, including the exit
examination, the cumulative incidence of cervical
intraepithelial neoplasia grade II or worse was higher
in the colposcopy arm (79/1000 person years) than in
the cytological surveillance arm (58/1000 person
years) (table 2). The adjusted relative risk for the risk
ofcervicalintraepithelialneoplasiagradeIIorworsein
the colposcopy arm compared to the other arm was
1.37 (95% confidence interval 1.19 to 1.57). Similarly,
forcervicalintraepithelialneoplasiagradeIIIorworse,
the cumulative incidence was higher in the immediate
colposcopy arm, although the difference between the
arms was less marked (adjusted relative risk 1.26, 1.04
to 1.53) (table 2). These patterns were also apparent
Women assessed for eligibility (n=13 956)
Potentially eligible (n=11 019)
Attended recruitment appointment and agreed to have eligibility confirmed (n=5748)
Consented to randomisation (n=5521)
Randomised (n=4476)
Attended first surveillance
smear and were subsequently
followed up according to
cytological surveillance policy
(repeat smears every six
months unless three
inadequate results, three
consecutive normal results,
or moderate or worse result)
(n=2116)
Did not attend for first
surveillance smear (n=51)
Randomised and confirmed to be eligible (n=4439)
Randomised to cytological surveillance (n=2223)
Attended exit examination (n=1296, 58.3%)
  CIN II/III outcome information from exit examination and medical
    record abstraction
Did not attend exit examination (n=927, 41.7%)
  CIN II/III outcome information from medical record abstraction only
Randomised to initial colposcopy (n=2216)
Eligible for first surveillance smear (n=2167) Attended for initial colposcopy examination (n=2065)
Ineligible (n=2937)
Excluded (n=5271):
  Did not attend recruitment appointment (n=4515)
  Attended but found not to be eligible (n=756)
Did not consent to randomisation (n=227)
Did not attend for initial colposcopy examination (n=151):
  Defaulted from initial examination (n=148)
  Deviations from protocol: repeat smear before colposcopy
    offered (n=3)
Had colposcopy examination,
with related interventions if
required, and followed up
accordingly (n=2061)
Did not have colposcopy
examination (pregnant,
refused, existing referral to
colposcopy, could not tolerate
speculum) (n=4)
Attended exit examination (n=1389, 62.7%)
  CIN II/III outcome information from exit examination and medical
    record abstraction
Did not attend exit examination (n=827, 37.3%)
  CIN II/III outcome information from medical record abstraction only
Left trial or referred to colposcopy before first surveillance
  smear (n=56):
    Left trial (n=48)
    Referred to colposcopy (n=8)
Not randomised (n=1045): 
  Not confirmed as eligible (n=1023)
 Excluded (n=22):
    Requested exit (n=7)
    GP requested exit (n=1)
    Lost contact (n=6)
    Medical reasons (n=6)
    Administrative error (n=2)
Randomised but ineligible (n=37): 
  Not eligible on basis of previous smear result/treatment (n=20)
 Repeat smear before first appointment (n=12)
  Medical reasons at/after first appointment (n=2)
  Exited from the trial before randomised (moved/died) (n=3)
Fig 1 | Flowchart of recruitment, randomisation, and follow-up of women (CIN=cervical intraepithelial neoplasia)
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and restricted it to women with no previous abnormal
cytology (table 3). The difference in cumulative inci-
dence between the trial arms was more pronounced in
younger women and in those whose index cytology
showed mild dyskaryosis (relative risk 1.54) rather
than borderline nuclear abnormalities (relative risk
1.17) (table 3). In younger women and those with
mild dyskaryosis at recruitment, the relative risks
were markedly higher for cervical intraepithelial neo-
plasia grade II or worse than for grade III or worse.
Thesepatternsweresimilarwhenwerestrictedtheana-
lysis to women who attended for the exit examination
(data not shown).
With regard to more severe disease than cervical
intraepithelial neoplasia grade III, there were seven
cases in the cytological surveillance arm and four in
the immediate colposcopy arm (relative risk
colposcopy v surveillance 0.58, 0.12 to 2.28). In the
surveillance arm, the specific diagnoses were adeno-
carcinoma with cervical glandular intraepithelial neo-
plasia and lymphatic space invasion (one case);
adenocarcinoma stage 1B1 (one case); squamous car-
cinomainlargeloopexcision(onecase);cervicalintra-
epithelial neoplasia grade III with stromal invasion in
large loop excision (one case); and microinvasion
(three cases). In the colposcopy arm, the diagnoses
wereadenocarcinomainsitu(onecase);squamouscar-
cinoma (one case); microinvasion (two cases).
Timing of detection of cervical intraepithelial neoplasia
grade II or worse
CervicalintraepithelialneoplasiagradeIIorworsewas
detected earlier in the colposcopy arm than in the sur-
veillance arm (fig 2; log rank P<0.001); this was also
evident when we repeated the analysis for cervical
intraepithelial neoplasia grade III or more severe dis-
ease (log rank P=0.005).
Among women randomised to immediate colpo-
scopy, the proportion of “management success,”—
that is, the proportion of cervical intraepithelial neo-
plasia grade II or worse detected at the immediate col-
poscopy—was78.8%(74.9%to82.5%);forgradeIIIor
worse, the proportion was similar (79.0%, 73.3% to
84.0%) (table 2). For cytological surveillance, the pro-
portionof“managementsuccess,”—thatis,thepropor-
tion of cervical intraepithelial neoplasia grade II or
worse detected during follow-up—was 76.9% (72.1%
to81.2%);forgradeIII,itwas87.0%(81.5%to91.4%).
Ahigherproportionofdiseasewasdetectedatexitin
the surveillance arm compared with the immediate
colposcopy arm (grade II or worse 23.1% v 7.1%;
grade III or worse 13.0% v 2.9%). Within the surveil-
lance arm, there was no difference in the proportions
by age or severity of index cytology of grade III or
worse detected at exit, but the proportion of women
with grade III or worse who had this detected at exit
was higher for those who did not have infection with
human papillomavirus of a type associated with high
risk for cervical cancer at recruitment than who had
such an infection (data not shown). Of the 25 cases of
Table 1 |Characteristics of women at enrolment, by trial arm. Figures are numbers
(percentages) of women
Cytological
surveillance Colposcopy
Total 2223 2216
Cytology status at enrolment:
Mild, with previous borderline nuclear abnormalities 57 (2.6) 60 (2.7)
Mild, no previous borderline nuclear abnormalities 732 (32.9) 727 (32.8)
Borderline nuclear abnormalities, with previous borderline nuclear
abnormalities
329 (14.8) 317 (14.3)
Borderline nuclear abnormalities, no previous borderline nuclear
abnormalities
1105 (49.7) 1112 (50.1)
Age (years):
20-29 982 (44.2) 978 (44.1)
30-39 596 (26.8) 596 (26.9)
40-49 459 (20.6) 455 (20.5)
50-59 186 (8.4) 187 (8.4)
Human papillomavirus (HPV) status:
High risk HPV 875 (39.4) 880 (39.7)
No high risk HPV 1147 (51.6) 1129 (50.9)
Not known* 201 (9.0) 207 (9.3)
Centre:
A 738 (33.2) 739 (33.3)
B 553 (24.9) 548 (24.7)
C 932 (41.9) 929 (41.9)
Ethnic group†:
White 2112 (95.0) 2108 (95.1)
Other‡ 98 (4.4) 91 (4.1)
Not stated 13 (0.6) 17 (0.8)
Post school education and training†:
None 620 (27.9) 615 (27.8)
Through work with formal qualifications 448 (20.2) 424 (19.1)
Qualification other than degree from college or university 634 (28.5) 627 (28.3)
Degree 502 (22.6) 537 (24.2)
Not stated 19 (0.9) 13 (0.6)
Employment status†:
Full time paid employment 1096 (49.3) 1082 (48.8)
Part time paid employment 512 (23.0) 508 (22.9)
Student 207 (9.3) 216 (9.7)
Not in paid employment 397 (17.9) 400 (18.1)
Not stated 11 (0.5) 10 (0.5)
Marital status†:
Married/living as married 1235 (55.6) 1177 (53.1)
Divorced/separated/widowed 298 (13.4) 303 (13.7)
Single 660 (29.7) 711 (32.1)
Not stated 30 (1.4) 25 (1.1)
Ever been pregnant†:
Yes 1459 (65.6) 1480 (66.8)
No 740 (33.3) 721 (32.5)
Not stated 24 (1.1) 15 (0.7)
Parity:
0 953 (42.9) 972 (43.9)
1 370 (16.6) 341 (15.4)
≥2 835 (37.6) 855 (38.6)
Not stated 65 (2.9) 48 (2.2)
Contraception†:
Use of pill or other hormonal contraceptives only 840 (37.8) 795 (35.9)
Use of barrier contraceptive only 272 (12.2) 306 (13.8)
Use of hormonal and barrier contraceptives 83 (3.7) 83 (3.7)
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detected at exit in the cytology arm, 10 were in
women who did not have a high risk human papillo-
mavirus infection at enrolment, 12 were in women
with such an infection, and three were in women of
unknown human papillomavirus status. Thus, about
half of the cases of cervical intraepithelial neoplasia
grade III or worse detected at exit in the cytology
arm might have been a result of new infection during
follow-up. Again within the surveillance arm, the pro-
portion of cervical intraepithelial neoplasia grade II or
worsedetectedatexitwashighereitherwhentheindex
cytology showed borderline nuclear abnormalities or
whenthewomandidnothaveahighriskhumanpapil-
lomavirus infection at recruitment.
Referral to colposcopy
In the cytological surveillance arm 19.1% (17.5% to
20.8%)womenwerereferredtocolposcopy.Inthecol-
poscopy arm, 8.0% (6.9% to 9.2%) were re-referred to
colposcopy during follow-up.
Anxiety and depression
Therewasnosignificantdifferenceintheproportionof
womenclassifiedaslikelytohavedepressionsixweeks
after the initial surveillance cytology test or the
immediate colposcopy (table 4). The proportion clas-
sified as likely to be anxious at this time point was sig-
nificantly higher in the surveillance arm than in the
immediate colposcopy arm. At subsequent time
points, the proportions of women who were anxious
or depressed were similar between the arms.
Other after effects
Significantly higher proportions of women rando-
mised to immediate colposcopy reported pain, bleed-
ing, or discharge compared with women in the
surveillance arm. Women in the colposcopy arm also
reported after effects that lasted longer and were more
severe (table 4).
Non-attendance
In the cytological surveillance arm, 229 (10.6%) of
women did not attend, whereas in the other arm, 151
(6.8%) of women failed to attend for immediate colpo-
scopy. Within the surveillance arm, 51 (2.4%) of
women failed to attend for the first surveillance cytol-
ogy, while 178 (8.2%) attended later than six months
after it was due. The proportions failing to attend or
attending late for surveillance cytology increased
slightly for the second (3.9% and 8.6%, respectively)
and third (5.8% and 7.9%, respectively) tests, but
declined for subsequent tests (about 3-4% and 1-4%,
respectively).
DISCUSSION
In this randomised controlled trial, the cumulative
incidence of cervical intraepithelial neoplasia grade II
orworseinwomenreferredforimmediatecolposcopy
washigherthaninthoserandomisedtocytologicalsur-
veillance. This difference was less marked for cervical
intraepithelial neoplasia grade III or worse and was
accounted for by grade II or worse detected at the
immediatecolposcopy.Aswould be expected,disease
was detected earlier in the colposcopy arm than in the
cytology arm. There was little difference between the
arms in the proportions of women who were anxious
or depressed. A higher proportion of women in the
colposcopy arm reported after effects, and these were
of longer duration and of greater severity. Non-atten-
dance was low in both arms.
Cervical intraepithelial neoplasia grade II or worse
The more marked difference between the arms in the
occurrence of cervical intraepithelial neoplasia grade
IIorworsethanintheoccurrenceofgradeIIIorworse
isprobablybecauseofspontaneousregressionofsome
cases of grade II in the surveillance arm. A similar pat-
Cytological
surveillance Colposcopy
None 1018 (45.8) 1023 (46.2)
Not stated 10 (0.5) 9 (0.4)
Physical activity†:
<1 time/week 879 (39.5) 885 (39.9)
1-3 times/week 534 (24.0) 491 (22.2)
>3 times/week 770 (34.6) 803 (36.2)
Not stated 40 (1.8) 37 (1.7)
Smoking status†:
Never smoker 1027 (46.2) 1016 (45.8)
Former smoker 383 (17.2) 368 (16.6)
Current smoker 783 (35.2) 810 (36.6)
Not stated 30 (1.4) 22 (1.0)
*Includes women whose samples were inadequate for analysis (n=28) and women who did not have human
papillomavirus test at recruitment (n=380), most of whom declined to provide sample because they were
menstruating at time of recruitment appointment.
†Enrolment questionnaires on sociodemographic characteristics not completed by 10 women in cytological
surveillance arm and 9 in colposcopy arm.
‡Comprises women in following categories defined by 1991 Census: black-Caribbean (n=65), black-African
(n=14), black-other (n=16), Indian (n=23), Pakistani (n=23), Bangladeshi (n=2), Chinese (n=16), other ethnic
group (n=30).
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Fig 2 |Comparison of proportion of women developing cervical
intraepithelial neoplasia II, III, or more severe disease over
time between trial arms
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2526andinUK
studies of women with mild dyskaryosis
29 or either
moderate or mild dyskaryosis.
27 This suggests that a
policy of immediate colposcopy can lead to overtreat-
ment, an increasingly recognised problem.
42 The pat-
tern of a more marked difference between the trial
arms for cervical intraepithelial neoplasia grade II or
worse than grade III or worse was apparent only for
women aged under 40. For this reason, we do not sup-
port the recent suggestion that women aged 35 or less
would benefit from immediate referral,
43 particularly
because of concerns regarding overtreatment and
after effects and effects on subsequent pregnancy
outcome
16 in women who have not completed their
families. Giannopoulos et al also concluded that it is
not possible to prioritise women for colposcopy on
the basis of age.
44
There was a marked difference between the arms in
thedetectionofcervicalintraepithelialneoplasiagrade
IIorworseforwomenwhoseindexcytologyindicated
mild dyskaryosis, but a much less marked difference
for cervical intraepithelial neoplasia grade III or
worse. For women whose index cytology showed bor-
derlinenuclearabnormalities,themagnitudeofthedif-
ference between trial arms was similar for cervical
intraepithelialneoplasiagradeIIorworseandcervical
intraepithelial neoplasia grade III or worse. This sug-
gests that following the most recent guidelines for
England
22andreferringforcolposcopyafteracytology
test showing mild dyskaryosis, a policy that is recom-
mended in several other countries,
21 could result in
substantial overtreatment.
As an approach to considering the public health
importance of any delay in detection associated with
cytological surveillance, we followed the ALTS trial
in defining management as successful for immediate
colposcopy when grade III or more severe disease
was detected at immediate colposcopy, and for cytolo-
gicalsurveillancewhengradeIIIorworsewasdetected
eitheratrecruitmentorduringfollow-up.
2526Applying
these definitions in our trial, in the immediate colpo-
scopyarm,justunder80%ofthetotalcasesofgradeIII
or worse were detected at recruitment; these propor-
tions were substantially higher than those observed in
ALTS. One possible explanation for this difference is
that in our trial, more than 90% of women undergoing
biopsy received a minimum of two punch biopsies,
whereas in ALTS, among those who had a biopsy
taken during immediate colposcopy, 68% underwent
Table 2 |Incidence of cervical intraepithelial neoplasia II, III, or worse, by trial arm and follow-
up period
Cytological surveillance Immediate colposcopy
No (%)
% of disease
detected No (%)
%ofdisease
detected
Total No of women randomised 2223 — 2216 —
Total person years of observation 6003 — 5906 —
Cervical intraepithelial neoplasia II, III, or worse*
Immediate colposcopy —— 369 (16.7) 78.8
Follow-up 269 (12.1) 76.9 66 (3.0) 14.1
Exit 81 (3.7) 23.1 33 (1.5) 7.1
Total 350† (15.7) 100 468‡ (21.1) 100
Cumulative incidence per 1000 person years:
Excluding cases detected at exit 45 — 74 —
Including cases detected at exit 58 — 79 —
Point prevalence at exit (%)§ 6.3 — 2.4 —
Cervical intraepithelial neoplasia III or worse*
Immediate colposcopy ——188 (8.5) 79.0
Follow-up 168 (7.6) 87.0 43 (1.9) 18.1
Exit 25 (1.1) 13.0 7 (0.3) 2.9
Total 193† (8.7) 100 238‡ (10.7) 100
Cumulative incidence per 1000 person years:
Excluding cases detected at exit 28 — 39 —
Including cases detected at exit 32 — 40 —
Point prevalence at exit (%)§ 1.9 — 0.5 —
*Relative risk (with cytology surveillance as reference) is 1.37 (1.19 to 1.57) for grade II, III, or worse and 1.26
(1.04 to 1.53) for grade III or III+. Relates to total cases. Adjusted for stratification variables (age group, index
cytology, human papillomavirus result, and recruitment centre).
†Seven cases in cytological surveillance arm had more severe disease (see text).
‡Four cases in colposcopy arm had more severe disease (see text).
§Denominator is 1296 women who attended exit examination in cytological surveillance arm, and 1389 women
in immediate colposcopy arm.
Table 3 |Cumulative incidence per 1000 person years of cervical intraepithelial neoplasia II, III, or worse, by trial arm and
age, enrolment cytology, human papillomavirus status at enrolment and trial centre
Subgroup
Cytological
surveillance
Immediate
colposcopy
Relativerisk(95%CI)*forcolposcopy
v
surveillance
No of
cases
Cumulative
incidence
No of
cases
Cumulative
incidence
Grade II and
worse CIN III+
Age (years):
20-29 203 78 286 113 1.45(1.21to1.74) 1.29 (1.02 to 1.65)
30-39 98 59 131 81 1.36(1.05to1.77) 1.40 (0.98 to 2.00)
40-49 36 29 41 33 1.10(0.70to1.73) 0.76 (0.37 to 1.54)
50-59 13 25 10 19 0.79(0.34to1.80) 0.79 (0.21 to 3.04)
Enrolment cytology:
Borderline nuclear abnormalities 171 44 201 53 1.17(0.95to1.43) 1.22 (0.91 to 1.64)
Mild dyskaryosis 179 84 267 128 1.54(1.28to1.86) 1.28 (1.00 to 1.64)
Analysis restricted to women
with no previous abnormal cytology
301 61 393 80 1.34(1.16to1.56) 1.29 (1.05 to 1.58)
*Adjusted for stratification variables (age group, index cytology, human papillomavirus result, and recruitment centre).
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36 The number of punch biopsies has
been found to be a key factor in identifying
disease.
3637 In the cytological surveillance arm in our
trial, the proportion of management successes for cer-
vical intraepithelial neoplasia grade III or worse was
87.0%, again higher than in ALTS, reflecting differ-
ences in the nature of surveillance, the proportions of
womenwithhighriskhumanpapillomavirusinfection,
and age distribution.
2526
Anxiety, depression, and other after effects
The lack of difference in proportions of women with
anxiety or depression between the trial arms after the
initialsixweekassessmentisconsistentwithaprevious
UK trial.
30 In our intention to treat analyses more
women randomised to immediate colposcopy than
cytologicalsurveillancereportedpain,bleeding,ordis-
charge and after effects of greater severity and longer
duration. Almost 20% of women on cytological sur-
veillancewerereferredforcolposcopyandsothecom-
parisons between the arms are likely to be
conservative. There has been no previous direct com-
parison of after effects between different management
policies. In the colposcopy arm, 39% reported pain
lasting for a median of two days, similar to a previous
study of women undergoing large loop excision (pro-
portion 40%, median duration three days).
45 The pro-
portions reporting discharge and bleeding were about
half those in the large loop excision study,
45 and the
duration of these complications was shorter.
Non-attendance
The level of non-attendance we observed in the cyto-
logical surveillance arm (2% of women failed to attend
for the first surveillance cytology, and 8% attended
more than six months after it was due) was lower than
that observed in previous studies,
2728 but in those stu-
dies surveillance required attendance at a colposcopy
clinic. It is also lower than the 15.7% reported for
women with low grade changes on cytology in the
areas in which human papillomavirus testing was
piloted in the UK
46 and might reflect the tendency for
trial participants to be more health conscious than the
general screening population. Some 7% of women
failed to attend for the immediate colposcopy, which
is higher than the 3% (2.1% to 4.1%) estimated in a
systematic review.
47
Strengths and limitations
The trial was population based. All eligible women
were invited to participate. The participation rate of
52% compares favourably with population based epi-
demiologicalstudies,
4849especiallyinviewofconcerns
aboutbarrierstowomen’sparticipationintrials.
5051As
reported elsewhere, the commonest reasons for non-
participation were that women preferred follow-up
by their own general practitioner and logistical issues
(suchastimingofrecruitmentclinics).
51Themostcom-
mon reasons for participation were altruism and wor-
ries about the cytology result. Although the
participation rate was higher in older women and
those living in the least deprived areas, the distribu-
tions of these factors did not differ between the trial
arms and so will not have affected the randomised
comparison.
With regards to generalisibility in the colposcopy
arm, 30% of women (26.7% to 33.5%; 214/713) with
mild dyskaryosis were found to have cervical intra-
epithelial neoplasia grade II or worse at the time of
the immediate colposcopy. This is similar to the 29%
observedin anotherUK serieswitha broadlycompar-
able age distribution during a similar time period.
44
Despite strenuous attempts to maximise
attendance,
24 a third of participants did not attend the
exitexamination.Thosewhodidnotattendweremore
likely to be young, be from non-white ethnic groups,
have cytology result at recruitment indicating mild
dyskaryosis,liveinareasinthetwomostdeprivedcate-
gories, and be smokers at recruitment. As several of
theseareriskfactorsforcervicalintraepithelialneopla-
sia grade II/III and cervical cancer,
52-54 the overall
cumulative incidence of grade II or worse was prob-
ably underestimated. The extent of the underestima-
tion is probably small, however, because the
proportion of previously undetected grade II or
Table 4 |Women’s reports of after effects, anxiety and depression, by trial arm: intention to
treat analysis. Figures are percentages (numbers) unless stated otherwise
Cytological
surveillance Immediate colposcopy P value
Pain*:
Any pain 15.0 (145/968) 38.9 (304/782) <0.001
Median (IQR) duration (days) 1 (1-2) 2 (1-3)
Moderate or more severe 5.8 (56/965) 18.6 (144/774) <0.001
Bleeding*:
Any bleeding 17.2 (166/967) 46.9 (366/781) <0.001
Median (IQR) duration (days) 1 (1-2) 5 (2-10)
Moderate or more severe 1.6 (16/961) 18.6 (144/772) <0.001
Discharge*:
Any discharge 8.6 (83/964) 34.2 (267/780) <0.001
Median (IQR) duration (days) 2 (1-4) 5 (2-12)
Moderate or more severe 3.7 (36/962) 17.1 (133/777) <0.001
Anxiety†:
6 weeks after procedure 13.4 (121/900) 7.9 (59/751) <0.001
12 months after randomisation 19.3 (218/1130) 16.4 (190/1161) 0.067
18 months after randomisation 17.6 (177/1008) 15.4 (162/1050) 0.193
24 months after randomisation 18.4 (177/962) 17.9 (179/1001) 0.766
30 months after randomisation 16.1 (143/887) 15.4 (146/949) 0.665
Depression‡:
6 weeks after procedure 7.5 (68/902) 6.6 (50/757) 0.461
12 months after randomisation 11.6 (132/1136) 9.5 (110/1162) 0.093
18 months after randomisation 11.2 (114/1016) 10.1 (106/1052) 0.399
24 months after randomisation 10.8 (104/964) 11.1 (111/1001) 0.831
30 months after randomisation 12.2 (108/887) 10.7 (101/948) 0.305
IQR=interquartile range.
*Determined by questionnaire six weeks after first surveillance cytology in cytological surveillance arm and six
weeks after colposcopy or any related procedures or appointments in colposcopy arm. Proportion of women
returning questionnaires on short term after effects was 78.4% in cytological surveillance arm and 84.7% in
colposcopy arm.
†≥11 on hospital anxiety and depression scale anxiety subscale.
‡≥8 on hospital anxiety and depression scale depression subscale.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 9 of 11worse in women who attended the exit examination
was low (6.3% in the cytological surveillance arm and
2.4%intheimmediatecolposcopyarmhadgradeIIor
worse; 1.9% and 0.5%, respectively, had grade III or
worse).Inaddition,inthecolposcopyarmthefrequen-
cies of cervical intraepithelial neoplasia grade II or
worse detected up to,but not including,the exit exam-
ination (14% for women with borderline nuclear
abnormalities and 32% for those with mild dyskaryo-
sis) were similar to figures from two studies that fol-
lowed participants in the NHS cervical screening
programme with borderline nuclear abnormalities or
mild dyskaryosis for five years (13% and 28%,
10 13%
and36%
55).Whenwerestrictedouranalysistowomen
who had attended the exit examination, the difference
between the trial arms was attenuated (relative risk
1.23, 1.03 to 1.47).
Conclusion
In women with low grade cytological abnormalities, a
policy of immediate colposcopy detects more cervical
intraepithelial neoplasia grade II or more severe dis-
ease and some more cervical intraepithelial neoplasia
grade III or worse compared with cytological surveil-
lance but can lead to overtreatment. This pattern is
more apparent when the index cytology result indi-
cates mild dyskaryosis rather than borderline nuclear
abnormalities.Furthermore,suchapolicyisassociated
with a higher rate of reported after effects, which are
more severe and of longer duration than those asso-
ciated with cytological surveillance. We conclude that
thereisnoclearbenefitofapolicyofimmediatecolpo-
scopy as although it detects more cervical intra-
epithelial neoplasia grade II or more severe disease, it
leads to a large number of referrals with no high grade
cervical intraepithelial neoplasia, overtreatment with
associated after effects in young women, and no clear
psychological benefit.
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